Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trials

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 455-463

  Falasca, Marco ^a   Selvaggi, Federico ^b   Buus, Richard ^a   Sulpizio, Sara ^b   Edling, Charlotte E ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Akt; Drug treatment; K Ras; MTOR; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Phosphatidylinositol 3 kinase

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; CURCUMIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; HISPIDULIN; INOSITOL POLYPHOSPHATE MYOINOSITOL 1,3,4,5,6 PENTAKISPHOSPHATE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; QLT 0254; SULFORAPHANE; SULINDAC; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; WORTMANNIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTEMISIA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; CLINICAL PRACTICE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; HUMAN; LIVER METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 79958177923     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677382     Document Type: Review

References (104)

1. Alrawashdeh, W.; Kocher, H. M., Pancreatic cancer. Clin. Evid., (Online) 2009, 2007.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E., Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60 (5), 277-300.
3. Cubilla, A. L.; Fitzgerald, P. J., Morphological patterns of primary nonendocrine human pancreas carcinoma. Cancer Res 1975, 35 (8), 2234-48.
4. Zuckerman, D. S.; Ryan, D. P., Adjuvant therapy for pancreatic cancer: a review. Cancer, 2008, 112 (2), 243-249.
5. Rosenberg, L., Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine. Int. J. Pancreatol., 1997, 22 (2), 81-93.
6. Bardeesy, N.; DePinho, R. A., Pancreatic cancer biology and genetics. Nat. Rev. Cancer, 2002, 2 (12), 897-909.
7. Hruban, R. H.; Goggins, M.; Parsons, J.; Kern, S. E., Progression model for pancreatic cancer. Clin Cancer Res., 2000, 6 (8), 2969-2972.
8. Schneider, G.; Siveke, J. T.; Eckel, F.; Schmid, R. M., Pancreatic cancer: basic and clinical aspects. Gastroenterology, 2005, 128 (6), 1606-1625
9. Hruban, R. H.; Wilentz, R. E.; Kern, S. E., Genetic progression in the pancreatic ducts. Am. J. Pathol., 2000, 156 (6), 1821-1825.
10. Aguirre, A. J.; Bardeesy, N.; Sinha, M.; Lopez, L.; Tuveson, D. A.; Horner, J.; Redston, M. S.; DePinho, R. A., Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev., 2003, 17 (24), 3112-3126.
11. Hingorani, S. R.; Wang, L.; Multani, A. S.; Combs, C.; Deramaudt, T. B.; Hruban, R. H.; Rustgi, A. K.; Chang, S.; Tuveson, D. A., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7 (5), 469-483.
12. Izeradjene, K.; Combs, C.; Best, M.; Gopinathan, A.; Wagner, A.; Grady, W. M.; Deng, C. X.; Hruban, R. H.; Adsay, N. V.; Tuveson, D. A.; Hingorani, S. R., Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell, 2007, 11 (3), 229-243.
13. Cantley, L. C., The phosphoinositide 3-kinase pathway. Science, 2002, 296 (5573), 1655-1657.
14. Yuan, T. L.; Cantley, L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27 (41), 5497-510.
15. Zhao, L.; Vogt, P. K., Class I PI3K in oncogenic cellular transformation. Oncogene, 2008, 27 (41), 5486-5496.
16. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E., High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304 (5670), 554.
17. Edling, C. E.; Selvaggi, F.; Buus, R.; Maffucci, T.; di Sebastiano, P.; Friess, H.; Innocenti, P.; Kocher, H. M.; Falasca, M., Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res., 2010, 16 (20), 4928-4937.
18. Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Morooka, T.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Ishikawa, O.; Ohigashi, H.; Nakamori, S.; Monden, M.; Aozasa, K., Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res., 2004, 10 (8), 2846-2850.
19. Ozaki-Ohgami, Y.; Iwamoto, A.; Yoshioka, S.; Tatebe, S.; Hirooka, Y.; Ikeguchi, M., Expression of phospho-akt and PTEN proteins predicts the survival of patientswith pancreatic cancer. Yonago Acta Medica, 2006, 49, 9-17.
20. Schlieman, M. G.; Fahy, B. N.; Ramsamooj, R.; Beckett, L.; Bold, R. J., Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer, 2003, 89 (11), 2110-2115.
21. Elghazi, L.; Weiss, A. J.; Barker, D. J.; Callaghan, J.; Staloch, L.; Sandgren, E. P.; Gannon, M.; Adsay, V. N.; Bernal-Mizrachi, E., Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology, 2009, 136 (3), 1091-1103.
22. Friday, B. B.; Adjei, A. A., K-ras as a target for cancer therapy. Biochim. Biophys. Acta, 2005, 1756 (2), 127-144.
23. Wang, J. Y.; Lian, S. T.; Chen, Y. F.; Yang, Y. C.; Chen, L. T.; Lee, K. T.; Huang, T. J.; Lin, S. R., Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett., 2002, 180 (2), 153-158.
24. Shibata, D.; Almoguera, C.; Forrester, K.; Dunitz, J.; Martin, S. E.; Cosgrove, M. M.; Perucho, M.; Arnheim, N., Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res., 1990, 50 (4), 1279-1283.
25. Dergham, S. T.; Dugan, M. C.; Kucway, R.; Du, W.; Kamarauskiene, D. S.; Vaitkevicius, V. K.; Crissman, J. D.; Sarkar, F. H., Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol., 1997, 21 (2), 127-143.
26. Hruban, R. H.; van Mansfeld, A. D.; Offerhaus, G. J.; van Weering, D. H.; Allison, D. C.; Goodman, S. N.; Kensler, T. W.; Bose, K. K.; Cameron, J. L.; Bos, J. L., K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol., 1993, 143 (2), 545-554.
27. Arvanitakis, M.; Van Laethem, J. L.; Parma, J.; De Maertelaer, V.; Delhaye, M.; Deviere, J., Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy, 2004, 36 (6), 535-542.
28. Chen, H.; Tu, H.; Meng, Z. Q.; Chen, Z.; Wang, P.; Liu, L. M., K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur. J. Surg. Oncol., 2010, 36 (7), 657-662.
29. Agbunag, C.; Bar-Sagi, D., Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res., 2004, 64 (16), 5659-5663.
30. Campbell, P. M.; Groehler, A. L.; Lee, K. M.; Ouellette, M. M.; Khazak, V.; Der, C. J., K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res., 2007, 67 (5), 2098-2106.
31. Castellano, E.; Downward, J., Role of RAS in the Regulation of PI 3-Kinase. Curr. Top Microbiol. Immunol., 2011, 346, 143-169.
32. Falasca, M., PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des., 2010, 16 (12), 1410-1416.
33. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B., The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol., 2010, 11 (5), 329-341.
34. Schonleben, F.; Qiu, W.; Remotti, H. E.; Hohenberger, W.; Su, G. H., PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch. Surg., 2008, 393 (3), 289-96.
35. Kang, S.; Denley, A.; Vanhaesebroeck, B.; Vogt, P. K., Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA, 2006, 103 (5), 1289-1294.
36. Benistant, C.; Chapuis, H.; Roche, S., A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene., 2000, 19 (44), 5083-5090.
37. Knobbe, C. B.; Reifenberger, G., Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol., 2003, 13 (4), 507-518.
38. Czauderna, F.; Fechtner, M.; Aygun, H.; Arnold, W.; Klippel, A.; Giese, K.; Kaufmann, J., Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res., 2003, 31 (2), 670-682.
39. Sujobert, P.; Bardet, V.; Cornillet-Lefebvre, P.; Hayflick, J. S.; Prie, N.; Verdier, F.; Vanhaesebroeck, B.; Muller, O.; Pesce, F.; Ifrah, N.; Hunault-Berger, M.; Berthou, C.; Villemagne, B.; Jourdan, E.; Audhuy, B.; Solary, E.; Witz, B.; Harousseau, J. L.; Himberlin, C.; Lamy, T.; Lioure, B.; Cahn, J. Y.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D., Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood, 2005, 106
40. Sawyer, C.; Sturge, J.; Bennett, D. C.; O'Hare, M. J.; Allen, W. E.; Bain, J.; Jones, G. E.; Vanhaesebroeck, B., Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res., 2003, 63 (7), 1667-1675.
41. Hamada, K.; Sasaki, T.; Koni, P. A.; Natsui, M.; Kishimoto, H.; Sasaki, J.; Yajima, N.; Horie, Y.; Hasegawa, G.; Naito, M.; Miyazaki, J.; Suda, T.; Itoh, H.; Nakao, K.; Mak, T. W.; Nakano, T.; Suzuki, A., The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev., 2005, 19 (17), 2054-2065.
42. Hickey, F. B.; Cotter, T. G., BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem., 2006, 281 (5), 2441-2450.
43. James, S. R.; Downes, C. P.; Gigg, R.; Grove, S. J.; Holmes, A. B.; Alessi, D. R., Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem. J., 1996, 315 (Pt 3), 709-713.
44. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol., 1997, 7 (4), 261-269.
45. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307 (5712), 1098-1101.
46. Romashkova, J. A.; Makarov, S. S., NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 1999, 401 (6748), 86-90.
47. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L., Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 2000, 60 (6), 1541-1545.
48. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96 (6), 857-868.
49. Cross, F. R., Starting the cell cycle: what's the point? Curr. Opin. Cell Biol., 1995, 7 (6), 790-797.
50. Datta, R.; Kojima, H.; Yoshida, K.; Kufe, D., Caspase-3-mediated cleavage of protein kinase C theta in induction of apoptosis. J. Biol. Chem., 1997, 272 (33), 20317-20320.
51. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C., Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998, 282 (5392), 1318-1321.
52. Ruggeri, B. A.; Huang, L.; Wood, M.; Cheng, J. Q.; Testa, J. R., Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog., 1998, 21 (2), 81-86.
53. Mohamedali, A.; Lea, N. C.; Feakins, R. M.; Raj, K.; Mufti, G. J.; Kocher, H. M., AKT1 (E17K) mutation in pancreatic cancer. Technol. Cancer Res. Treat., 2008, 7 (5), 407-408.
54. Laurent-Puig, P.; Lievre, A.; Blons, H., Mutations and response to epidermal growth factor receptor inhibitors. Clin. Cancer Res., 2009, 15 (4), 1133-1139.
55. http://www.sanger.ac.uk/genetics/CGP/cosmic/, Sanger catalogue of somatic mutations.
56. Maehama, T.; Dixon, J. E., PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol., 1999, 9 (4), 125-128.
57. Cantley, L. C.; Neel, B. G., New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA, 1999, 96 (8), 4240-4245.
58. Sulis, M. L.; Parsons, R., PTEN: from pathology to biology. Trends Cell Biol., 2003, 13 (9), 478-483.
59. Asano, T.; Yao, Y.; Zhu, J.; Li, D.; Abbruzzese, J. L.; Reddy, S. A., The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene, 2004, 23 (53), 8571-8580.
60. Ma, J.; Sawai, H.; Matsuo, Y.; Ochi, N.; Yasuda, A.; Takahashi, H.; Wakasugi, T.; Funahashi, H.; Sato, M.; Takeyama, H., IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J. Surg. Res., 2010, 160 (1), 90-101.
61. Ma, J.; Sawai, H.; Ochi, N.; Matsuo, Y.; Xu, D.; Yasuda, A.; Takahashi, H.; Wakasugi, T.; Takeyama, H., PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol. Cell Biochem., 2009, 331 (1-2), 161-171.
62. Hill, R.; Calvopina, J. H.; Kim, C.; Wang, Y.; Dawson, D. W.; Donahue, T. R.; Dry, S.; Wu, H., PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010, 70 (18), 7114-24.
63. Foster, K. G.; Fingar, D. C., Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem., 2010, 285 (19), 14071-14077.
64. Jefferies, H. B.; Fumagalli, S.; Dennis, P. B.; Reinhard, C.; Pearson, R. B.; Thomas, G., Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J., 1997, 16 (12), 3693-3704.
65. Bellizzi, A. M.; Bloomston, M.; Zhou, X. P.; Iwenofu, O. H.; Frankel, W. L., The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl. Immunohistochem. Mol. Morphol., 2010, 18 (5), 442-447.
66. Powis, G.; Bonjouklian, R.; Berggren, M. M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W. F.; Dodge, J.; Grindey, G.; Vlahos, C. J., Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res., 1994, 54 (9), 2419-2423.
67. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269 (7), 5241-8.
68. Bondar, V. M.; Sweeney-Gotsch, B.; Andreeff, M.; Mills, G. B.; McConkey, D. J., Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther., 2002, 1 (12), 989-997.
69. Reichert, M.; Saur, D.; Hamacher, R.; Schmid, R. M.; Schneider, G., Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res., 2007, 67 (9), 4149-4156.
70. Takeda, A.; Osaki, M.; Adachi, K.; Honjo, S.; Ito, H., Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas, 2004, 28 (3), 353-358.
71. Perugini, R. A.; McDade, T. P.; Vittimberga, F. J., Jr.; Callery, M. P., Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J. Surg. Res., 2000, 90 (1), 39-44.
72. Chaussade, C.; Rewcastle, G. W.; Kendall, J. D.; Denny, W. A.; Cho, K.; Gronning, L. M.; Chong, M. L.; Anagnostou, S. H.; Jackson, S. P.; Daniele, N.; Shepherd, P. R., Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J., 2007, 404 (3), 449-458.
73. Ng, S. S. W.; Tsao, M. S.; Chow, S.; Hedley, D. W., Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res., 2000, 60 (19), 5451-5455.
74. Ng, S. S.; Tsao, M. S.; Nicklee, T.; Hedley, D. W., Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res., 2001, 7 (10), 3269-3275.
75. Liu, D.; Zhang, Y.; Dang, C.; Ma, Q.; Lee, W.; Chen, W., siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol. Rep., 2007, 18 (3), 673-677.
76. Yau, C. Y.; Wheeler, J. J.; Sutton, K. L.; Hedley, D. W., Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res., 2005, 65 (4), 1497-1504.
77. Simon, P. O., Jr.; McDunn, J. E.; Kashiwagi, H.; Chang, K.; Goedegebuure, P. S.; Hotchkiss, R. S.; Hawkins, W. G., Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int. J. Cancer, 2009, 125 (4), 942-951.
78. Yip-Schneider, M. T.; Wiesenauer, C. A.; Schmidt, C. M., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J. Gastrointest. Surg., 2003, 7 (3), 354-363.
79. Fujiwara, M.; Izuishi, K.; Sano, T.; Hossain, M. A.; Kimura, S.; Masaki, T.; Suzuki, Y., Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J. Exp. Clin. Cancer Res., 2008, 27, 76.
80. Parsons, C. M.; Muilenburg, D.; Bowles, T. L.; Virudachalam, S.; Bold, R. J., The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res., 2010, 30 (9), 3279-3289.
81. Ito, D.; Fujimoto, K.; Mori, T.; Kami, K.; Koizumi, M.; Toyoda, E.; Kawaguchi, Y.; Doi, R., In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer, 2006, 118 (9), 2337-2343.
82. Okada, T.; Sawada, T.; Kubota, K., Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. Hepatogastroenterology, 2007, 54 (79), 2129-2133.
83. Cao, P.; Maira, S. M.; Garcia-Echeverria, C.; Hedley, D. W., Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br. J. Cancer, 2009, 100 (8), 1267-1276.
84. Garrido-Laguna, I.; Tan, A. C.; Uson, M.; Angenendt, M.; Ma, W. W.; Villaroel, M. C.; Zhao, M.; Rajeshkumar, N. V.; Jimeno, A.; Donehower, R.; Iacobuzio-Donahue, C.; Barrett, M.; Rudek, M. A.; Rubio-Viqueira, B.; Laheru, D.; Hidalgo, M., Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer, 2010, 103 (5), 649-655.
85. Roy, S. K.; Srivastava, R. K.; Shankar, S., Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J. Mol. Signal, 2010, 5, 10.
86. Kallifatidis, G.; Labsch, S.; Rausch, V.; Mattern, J.; Gladkich, J.; Moldenhauer, G.; Buchler, M. W.; Salnikov, A. V.; Herr, I., Sulforaphane Increases Drug-mediated Cytotoxicity Toward Cancer Stem-like Cells of Pancreas and Prostate. Mol. Ther., 2010.
87. He, L.; Wu, Y.; Lin, L.; Wang, J.; Chen, Y.; Yi, Z.; Liu, M.; Pang, X., Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. Cancer Sci., 2010.
88. Falasca, M.; Chiozzotto, D.; Godage, H. Y.; Mazzoletti, M.; Riley, A. M.; Previdi, S.; Potter, B. V.; Broggini, M.; Maffucci, T., A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br. J. Cancer, 102 (1), 104-114.
89. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A. B.; Aggarwal, B. B., Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett., 2008, 267 (1), 133-164.
90. Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N. A.; Hong, S. M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M. G.; Rudek, M. A.; Ravi, R.; Maitra, A., Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther., 2010, 9 (8), 2255-64.
91. Mach, C. M.; Mathew, L.; Mosley, S. A.; Kurzrock, R.; Smith, J. A., Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res., 2009, 29 (6), 1895-1899.
92. Bar-Sela, G.; Epelbaum, R.; Schaffer, M., Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem., 2010, 17 (3), 190-197.
93. Stan, S. D.; Singh, S. V.; Brand, R. E., Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol Hepatol., 2010, 7 (6), 347-356.
94. Olive, K. P.; Tuveson, D. A., The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res., 2006, 12 (18), 5277-5287.
95. Di Marco, M.; Di Cicilia, R.; Macchini, M.; Nobili, E.; Vecchiarelli, S.; Brandi, G.; Biasco, G., Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol. Rep., 2010, 23 (5), 1183-1192.
96. Burris, H. A., 3rd; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15 (6), 2403-2413.
97. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25 (15), 1960-1966.
98. Fountzilas, G.; Bobos, M.; Kalogera-Fountzila, A.; Xiros, N.; Murray, S.; Linardou, H.; Karayannopoulou, G.; Koutras, A. K.; Bafaloukos, D.; Samantas, E.; Christodoulou, C.; Economopoulos, T.; Kalogeras, K. T.; Kosmidis, P., Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest., 2008, 26 (8), 784-793.
99. Philip, P. A.; Benedetti, J.; Corless, C. L.; Wong, R.; O'Reilly, E. M.; Flynn, P. J.; Rowland, K. M.; Atkins, J. N.; Mirtsching, B. C.; Rivkin, S. E.; Khorana, A. A.; Goldman, B.; Fenoglio-Preiser, C. M.; Abbruzzese, J. L.; Blanke, C. D., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol., 2010, 28 (22), 3605-3610.
100. Marsh Rde, W.; Rocha Lima, C. M.; Levy, D. E.; Mitchell, E. P.; Rowland, K. M., Jr.; Benson, A. B., 3rd, A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol., 2007, 30 (1), 26-31.
101. Javle, M. M.; Shroff, R. T.; Xiong, H.; Varadhachary, G. A.; Fogelman, D.; Reddy, S. A.; Davis, D.; Zhang, Y.; Wolff, R. A.; Abbruzzese, J. L., Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer, 2010, 10, 368.
102. Wolpin, B. M.; Hezel, A. F.; Abrams, T.; Blaszkowsky, L. S.; Meyerhardt, J. A.; Chan, J. A.; Enzinger, P. C.; Allen, B.; Clark, J. W.; Ryan, D. P.; Fuchs, C. S., Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol., 2009, 27 (2), 193-198.
103. Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; Abbruzzese, J. L.; Ng, C. S.; Badmaev, V.; Kurzrock, R., Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14 (14), 4491-4499.
104. Engelman, J. A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A. R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S. A.; Song, Y.; Chirieac, L. R.; Kaur, R.; Lightbown, A.; Simendinger, J.; Li, T.; Padera, R. F.; Garcia-Echeverria, C.; Weissleder, R.; Mahmood, U.; Cantley, L. C.; Wong, K. K., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med., 2008, 14 (12), 1351-1356.